NIA Alzheimer's Drug-Development Program
Funds collaborative research alliances that accelerate Alzheimer's drug development in the United States.
The NIA Alzheimer's Drug-Development Program (ADDP), funded under FOAs PAR-24-223 and PAR-25-297, supports drug discovery and development studies targeting Alzheimer's disease through U01 cooperative agreements. As a cooperative agreement, NIA scientific staff play an active and substantive role in project direction throughout the award period — reviewing milestones, participating in scientific de…
Drug discovery and development targeting Alzheimer's disease, including drug repositioning, combination therapy, and translational bioinformatics approaches funded as cooperative agreements.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see the timeline